SRS Treatment Research Articles

Stereotactic Radiosurgery for Intracranial Breast Metastases: A Systematic Review and Meta-Analysis

Background/Objectives: To determine the impact of stereotactic radiosurgery on outcomes of metastatic breast cancer with intracranial metastases. Methods: We systematically searched the PubMed and EMBASE databases for studies published between 1 January 1990 and 1 August 2024. Primary research articles evaluating the outcomes of stereotactic radiosurgery on intracranial metastases from breast cancer were included. Adverse events were defined as leptomeningeal disease, radiation necrosis, seizure, and headache. The pooled estimate was calculated using the DerSimonian and Laird approach. Results: Sixteen studies encompassing 1228 patients met the inclusion criteria. Our analysis revealed a median survival duration of 13.1 ± 3.8 months and a pooled 1-year overall survival rate of 53.1% after SRS treatment. There was a 29% local recurrence rate at 1 year and a 35% overall distant recurrence rate. In addition, our analysis found a relatively low rate of acute adverse events at 15.5%. Conclusions: SRS demonstrates promising efficacy and safety in managing intracranial metastases from breast cancer, with a favorable toxicity profile.

Cochlear Implantation Outcomes in Patients With Sporadic Inner Ear Schwannomas With and Without Simultaneous Tumor Resection.

Describe a single institution's cochlear implant outcomes for patients with inner ear schwannomas (IES) in the setting of various tumor management strategies (observation, surgical resection, or stereotactic radiosurgery [SRS]). Single-institution retrospective review. Patients diagnosed with isolated, sporadic IES who underwent cochlear implantation (CI). CI with or without IES treatment. Speech perception outcomes, tumor status. Twelve patients with IES underwent CI with a median audiologic and radiologic follow-up of 12 months. Six patients underwent complete resection of the tumor at the time of CI, four underwent tumor observation, and two underwent SRS before CI. At 1 year after CI for all patients, the median consonant-nucleus-consonant (CNC) word score was 55% (interquartile range, 44-73%), and the median AzBio sentence in quiet score was 77% (interquartile range, 68-93%). Overall, those with surgical resection performed similarly to those with tumor observation (CNC 58 versus 61%; AzBio in quiet 74 versus 91%, respectively). Patients who underwent tumor resection before implantation had a wider range of speech performance outcomes compared with patients who underwent tumor observation. Two patients had SRS treatment before CI (10 months previous and same-day as CI) with CNC word scores of 6 and 40%, respectively. Patients with IES who underwent CI demonstrated similar speech performance outcomes (CNC 56% and AzBio 82%), when compared with the general cochlear implant population. Patients who underwent either tumor observation or surgical resection performed well after CI.

1384: Clinical Implementation of Prosoma Core for SRS treatments.

1384: Clinical Implementation of Prosoma Core for SRS treatments.

2130: Comparison of fractionated SRS treatment quality amongst multiple stereotactic delivery platforms

2130: Comparison of fractionated SRS treatment quality amongst multiple stereotactic delivery platforms

Investigation of a novel 2.5 MV sintered diamond target beam for intracranial linac-based stereotactic treatments.

This work investigates the small-field dosimetric characteristics of a 2.5 MV sintered diamond target beam and its feasibility for use in linac-based intracranial stereotactic treatments. Due to the increased proportion of low energy photons in the low-Z beam, it was hypothesized that this novel beam would provide sharper dose fall-off compared to the 6 MV beam owing to the reduced energy, and therefore range, of secondary electrons. Stereotactic treatments of ocular melanoma and trigeminal neuralgia were simulated for 2.5 MV low-Z and 6 MV beams using Monte Carlo to calculate dose in a voxelized anatomical phantom. Two collimation methods were investigated, including a 5x3 mm2 HDMLC field and a 4 mm cone to demonstrate isolated and combined effects of geometric and radiological contributions to the penumbral width. The measured 2.5 MV low-Z dosimetric profiles demonstrated reduced penumbra by 0.5 mm in both the inline and crossline directions across all depths for both collimation methods, compared to 6 MV. In both treatment cases, the 2.5 MV low-Z beam collimated with the 4 mm cone produced the sharpest dose fall off in profiles captured through isocenter. This improved fall-off resulted in a 59% decrease to the maximum brainstem dose in the trigeminal neuralgia case for the 2.5 MV low-Z MLC collimated beam compared to 6 MV. Reductions to the maximum and mean doses to ipsilateral and contralateral OARs in the ocular melanoma case were observed for the 2.5 MV low-Z beam compared to 6 MV with both collimation methods. While the low dose rate of this novel beam prohibits immediate clinical translation, the results of this study support the further development of this prototype beam to decrease toxicity in intracranial SRS treatments.&#xD.

330 Dosimetric comparison of two Treatment Planning Systems (TPS) for SRS treatments

330 Dosimetric comparison of two Treatment Planning Systems (TPS) for SRS treatments

Evaluating stereotactic accuracy with patient-specific MRI distortion corrections for frame-based radiosurgery.

This study examines how MRI distortions affect frame-based SRS treatments and assesses the need for clinical distortion corrections. The study included 18 patients with 80 total brain targets treated using frame-based radiosurgery. Distortion within patients' MRIs were corrected using Cranial Distortion Correction (CDC) software, which utilizes the patient's CT to alter planning MRIs to reduce inherent intra-cranial distortion. Distortion was evaluated by comparing the original planning target volumes (PTVORIG) to targets contoured on corrected MRIs (PTVCORR). To provide an internal control, targets were also re-contoured on uncorrected (PTVRECON) MRIs. Additional analysis was done to assess if 1mm expansions to PTVORIG targets would compensate for patient-specific distortions. Changes in target volumes, DICE and JACCARD similarity coefficients, minimum PTV dose (Dmin), dose to 95% of the PTV (D95%), and normal tissue receiving 12Gy (V12Gy), 10Gy (V10Gy), and 5Gy (V5Gy) were calculated and evaluated. Student's t-tests were used to determine if changes in PTVCORR were significantly different than intra-contouring variability quantified by PTVRECON. PTVRECON and PTVCORR relative changes in volume were 6.19%±10.95% and 1.48%±32.92%. PTVRECON and PTVCORR similarity coefficients were 0.90±0.08 and 0.73±0.16 for DICE and 0.82±0.12 and 0.60±0.18 for JACCARD. PTVRECON and PTVCORR changes in Dmin were -0.88%±8.77% and -12.9±17.3%. PTVRECON and PTVCORR changes in D95% were -0.34%±5.89 and -8.68%±13.21%. The 1mm expanded PTVORIG targets did not entirely cover 14 of the 80 PTVCORR targets. Normal tissue changes (V12Gy, V10Gy, V5Gy) calculated with PTVRECON were (-0.09%±7.39%, -0.38%±5.67%, -0.08%±2.04%) and PTVCORR were (-2.14%±7.34%, -1.42%±5.45%, -0.61%±1.93%). Except for V10Gy, all PTVCORR changes were significantly different (p<0.05) than PTVRECON. MRIs used for SRS target delineation exhibit notable geometric distortions that may compromise optimal dosimetric accuracy. A uniform 1mm expansion may result in geometric misses; however, the CDC algorithm provides a feasible solution for rectifying distortions, thereby enhancing treatment precision.

Technical note: Patient-specific quality assurance for multi-target single-isocenter SRS-A target-specific approach.

As radiotherapy techniques advance, so do planning methods for multi-target intracranial SRS cases. Multi-target-single-isocenter (MTSI) planning offers high-precision beam delivery with shortened duration. However, accommodating all targets in a single Patient-Specific-Quality-Assurance (PSQA) with QA devices like SRS MapCHECK (SRS MC) is generally impractical. Consequently, we conducted PSQA, using a custom script, by relocating each Target or Neighboring-Target-Group (T-NTG) relative to the beam isocenter on the PSQA device, ensuring each target's dose coverage at high precision. SRS treatment plans use 6MV-FFF beams, consisting of four Volumetric Modulated ARC Therapy (VMAT) arcs, including one full-arc and three half arcs with couch-kicks. A custom script calculated T-NTG coordinates relative to the beam isocenter. QA verification plans were created for each T-NTG, redefining the beam isocenter for precise alignment with the center of the SRS MC. CBCT images were acquired during PSQA for SRS MC alignment, and gamma-index analysis (GIA) was performed. A single-tail paired t-test assessed the passing rate (PR) for 75 QA verification plans. GIA with l.0mm/2.0% criteria for each QA plan yielded a PR>95.5%, with an average of 98.9%. Plans achieving PR>99.0% and>97.0% constituted 63% and 92% of studied plans, respectively. Statistical significance was observed in a t-test with an ideal PR value of 100%, while insignificance was found with a PR value of 99%, suggesting that PSQA for individual targets consistently approaches 99% PR. In MTSI cases using 6MV-FFF beams, targets within the lateral dose-fall-off region require careful verification for acceptability. Our clinical study on individual T-NTG relocation demonstrates that the presented PSQA methods are generally acceptable, supported by a statistically insignificant PR against a 99% PR value. Presented statistical analysis results indicate that the proposed PSQA approach can serve as a reliable tool in clinical settings.

Gafchromic EBT3 film provides equivalent dosimetric performance to EBT-XD film for stereotactic radiosurgery dosimetry

The accurate assessment of film results is highly dependent on the methodology and techniques used to process film. This study aims to compare the performance of EBT3 and EBT-XD film for SRS dosimetry using two different film processing methods. Experiments were performed in a solid water slab and an anthropomorphic head phantom. For each experiment, the net optical density of the film was calculated using two different methods; taking the background (initial) optical density from 1) an unirradiated film from the same film lot as the irradiated film (stock to stock (S-S) method), and 2) a scan of the same piece of film taken prior to irradiation (film to film (F-F) method). EBT3 and EBT-XD performed similarly across the suite of experiments when using the green channel only or with triple channel RGB dosimetry. The dosimetric performance of EBT-XD was improved across all colour channels by using an F-F method, particularly for the blue channel. In contrast, EBT3 performed similarly well regardless of the net optical density method used. Across 21 SRS treatment plans, the average per-pixel agreement between EBT3 and EBT-XD films, normalised to the 20 Gy prescription dose, was within 2% and 4% for the non-target (2—10 Gy) and target (> 10 Gy) regions, respectively, when using the F-F method. At doses relevant to SRS, EBT3 provides comparable dosimetric performance to EBT-XD. In addition, an S-S dosimetry method is suitable for EBT3 while an F-F method should be adopted if using EBT-XD.

1275: Commissioning of Prosoma Core for SRS treatments.

1275: Commissioning of Prosoma Core for SRS treatments.

2647: Setup of SRS treatment with open-face mask using Surface Guided Radiotherapy and head adjuster

2647: Setup of SRS treatment with open-face mask using Surface Guided Radiotherapy and head adjuster

Treatment Planning Methods for Dose Painting by Numbers Treatment in Gamma Knife Radiosurgery

PURPOSEDose painting radiotherapy delivers a non-uniform dose to tumours to account for heterogeneous radiosensitivity. With recent and ongoing development of Gamma Knife (GK) machines making large-volume brain tumour treatments more practical, it is increasingly feasible to deliver dose painting treatments. The increased prescription complexity means automated treatment planning is greatly beneficial, and the impact of dose painting on SRS plan quality has not yet been studied. This research investigates the plan quality achievable for GK SRS dose painting treatments when using optimisation techniques and automated isocentre placement in treatment planning. METHODS & MATERIALSDose painting prescription functions with varying parameters are applied to convert voxel image intensities to prescriptions for ten sample cases. To study achievable plan quality and optimisation, clinically-placed isocentres are used with each dose painting prescription, and optimised using a semi-infinite linear programming formulation. To study automated isocentre placement, a grassfire sphere-packing algorithm and a clinically available Leksell Gamma Plan isocentre fill algorithm are used. Plan quality for each optimised treatment plan is measured with dose painting SRS metrics. RESULTSOptimisation can be used to find high quality dose painting plans, and plan quality is affected by the dose painting prescription method. Polynomial function prescriptions show better achievable plan quality than sigmoid function prescriptions even with high mean dose boost. Automated isocentre placement is shown as a feasible method for dose painting SRS treatment, and increasing the number of isocentres improves plan quality. The computational solve time for optimisation is within 5 minutes in most cases, which is suitable for clinical planning. CONCLUSIONSThe impact of dose painting prescription method on achievable plan quality is quantified in this study. Optimisation and automated isocentre placement are shown as possible treatment planning methods to obtain high quality plans.

Stereotactic Radiosurgery for Women Older than 65 with Breast Cancer Brain Metastases.

Breast cancer is the second most common cause of brain metastases (BM). Despite increasing incidence of BM in older women, there are limited data on the optimal management of BM in this age group. In this study, we assessed the survival outcomes and treatment patterns of older breast cancer patients ≥65 years old with BM compared to younger patients at our institution. An IRB-approved single-institutional retrospective review of biopsy-proven breast cancer patients with BM treated with 1- to 5-fraction stereotactic radiation therapy (SRS) from 2015 to 2020 was performed. Primary endpoint was intracranial progression-free survival (PFS) defined as the time interval between the end of SRS to the date of the first CNS progression. Secondary endpoints were overall survival (OS) from the end of SRS and radiation treatment patterns. Kaplan-Meier estimates and Cox proportional hazard regression method were used for survival analyses. A total of 112 metastatic breast cancer patients with BMs were included of which 24 were ≥65 years old and 88 were <65 years old. Median age at RT was 72 years (range 65-84) compared to 52 years (31-64) in younger patients. There were significantly higher number of older women with ER/PR positive disease (75% vs. 49%, p = 0.036), while younger patients were more frequently triple negative (32% vs. 12%, p = 0.074) and HER2 positive (42% vs. 29%, p = 0.3). Treatment-related adverse events were similar in both groups. Overall, 14.3% patients had any grade radiation necrosis (RN) (older vs. young: 8.3% vs. 16%, p = 0.5) while 5.4% had grade 3 or higher RN (0% vs. 6.8%, p = 0.7). Median OS after RT was poorer in older patients compared to younger patients (9.5 months vs. 14.5 months, p = 0.037), while intracranial PFS from RT was similar between the two groups (9.7 months vs. 7.1 months, p = 0.580). On univariate analysis, significant predictors of OS were age ≥65 years old (hazard risk, HR = 1.70, p = 0.048), KPS ≤ 80 (HR = 2.24, p < 0.001), HER2 positive disease (HR = 0.46, p < 0.001), isolated CNS metastatic disease (HR = 0.29, p < 0.001), number of brain metastases treated with RT (HR = 1.06, p = 0.028), and fractionated SRS (HR = 0.53, p = 0.013). On multivariable analysis, KPS ≤ 80, HER2 negativity and higher number of brain metastases predicted for poorer survival, while age was not a significant factor for OS after adjusting for other variables. Patients who received systemic therapy after SRS had a significantly improved OS on univariate and multivariable analysis (HR = 0.32, p < 0.001). Number of brain metastases treated was the only factor predictive of worse PFS (HR = 1.06, p = 0.041), which implies a 6% additive risk of progression for every additional metastasis treated. Although older women had poorer OS than younger women, OS was similar after adjusting for KPS, extracranial progression, and systemic therapy; and there was no difference in rates of intracranial PFS, neurological deaths, and LMD in the different age groups. This study suggests that age alone may not play an independent role in treatment-selection and that outcomes for breast cancer patients with BMs and personalized decision-making including other clinical factors should be considered. Future studies are warranted to assess neurocognitive outcomes and other radiation treatment toxicities in older patients.

RADT-46. STEREOTACTIC RADIOSURGERY FOR CYSTIC AND SOLID INTRACRANIAL HEMANGIOBLASTOMAS: A SINGLE-INSTITUTION RETROSPECTIVE SERIES

Abstract INTRODUCTION Intracranial hemangioblastoma is a rare neoplasm that poses significant challenges in clinical management. Hemangioblastomas are characterized by unique radiological features into cystic or solid tumors. Out study aims to evaluate the role of SRS in the management of cystic and solid hemangioblastomas in a single institution setting. METHODS We conducted a retrospective analysis of clinical and radiological outcomes of patients with intracranial hemangioblastomas treated with CyberKnife SRS at our institute between 1998 and 2023. The follow-up data were available for 93 intracranial hemangioblastomas in 23 patients. Ten (43.5%) patients presented with 23 (25.6%) cystic hemangioblastomas, while 13 (56.5%) patients had 70 (75.3%) solid hemangioblastomas at the time of SRS treatment. The median age was 36 years and the median tumor volume accounted for 0.43 cc. The SRS was administered with the median single-fraction equivalent dose (SFED) of 20 Gy at the 77% of the median isodose line. RESULTS At a one-year follow-up, 11 initially solid hemangioblastomas developed cystic formation, resulting in a total of 34 (36.6%) cystic hemangioblastomas and 59 (63.4%) solid hemangioblastomas across 13 and 10 patients, respectively. Among these, 84.6% exhibited peritumoral edema prior to the onset of cystic formation. For 37 solid hemangioblastomas accompanied by peritumoral edema, SRS was administered before cystic transformation, remaining solid throughout the latest follow-up. Over a median follow-up period of 59 months (range: 3-260), 6 (17.6%) cystic and 13 (22%) solid hemangioblastomas progressed. The 5-year local tumor control (LTC) rate for intracranial hemangioblastomas was 84.7%, with 97% and 76.9% in cystic and solid lesions, respectively. CONCLUSION Our study illustrates the largest single-institutional long-term retrospective analysis of intracranial hemangioblastomas treated with SRS to date. Early SRS treatment at the time of edema may prevent cystic hemangioblastoma development and provides durable treatment outcomes for patients with both cystic and solid hemangioblastomas in long-term.

Toward an improved assessment of dose conformity in radiotherapy.

Evaluation of dose conformity is important to ensure minimum dose to normal tissue and sufficient dose coverage of the planning target volume (PTV). The existing conformity indices depend on the PTV volume and do not differentiate between two different scenarios: overdosing normal tissue and underdosing PTV. In this study, we introduce a novel index to assess conformity of dose distributions in radiotherapy. The suggested conformity index is defined by the ratio of the volume representing actual "non-conformity" of the planned dose and the volume representing acceptable "non-conformity." The latter volume is produced by expanding the PTV. If both the average distance ( ) between the reference isodose surface and planning target volume and arbitrarily selected PTV expansion margin ( ) are much smaller than the size of the PTV, approximately equals the ratio . In this work, was utilized to analyze 90 cases of brain metastases treated with stereotactic radiation therapy (SRS) and 102 cases of lung cancer treated with stereotactic body radiation therapy (SBRT). For =0.1cm, all considered SRS treatment plans were characterized by while 2 out of 102 SBRT plans had . The average values of for SRS and SBRT plans were 0.31 and 0.43, respectively. For =0.2cm, all studied treatment plans had , and the average values of for SRS and SBRT plans were 0.15 and 0.25, respectively. The suggested conformity index varies less with PTV volume than the RTOG and Riet-Paddick indices frequently used for evaluation of dose conformity. In addition, can be expressed as a sum of two terms which describe "over-coverage" and "under-coverage" of the treatment target. The results confirm that can be used for evaluation of dose conformity in SRS and SBRT.

MODL-27. INTEGRATING OVERALL SURVIVAL AND TUMOR CONTROL PROBABILITY MODELS TO PREDICT LOCAL PROGRESSION AFTER BRAIN METASTASIS RADIOSURGERY

Abstract PURPOSE Stereotactic radiosurgery (SRS) for brain metastases has competing goals of maximizing local control and minimizing toxicity. Tumor control probability (TCP) models predict decreasing risk of local progression (LP) with dose escalation. However, many patients die from extracranial disease prior to local progression and may not require maximally aggressive treatment, which increases risk of toxicity. Better tools to assess patients’ risk of LP after SRS could help practitioners personalize SRS treatment to maximize therapeutic ratio. Here we assess whether simultaneous modeling of TCP and overall survival (OS) can improve prediction of LP after SRS. METHODS Records of patients undergoing SRS at a single institution were reviewed retrospectively. Using established OS and TCP models, the probability of one-year survival [p(OS)] and probability of one-year LP [p(LP)]) were calculated for each patient and each metastasis, respectively. Joint-probability was used to combine the models [p(LP,OS)=p(LP)*p(OS)]. Analyses were conducted at the individual-metastasis and whole-patient levels. Fine-Gray regression was used to model the effect of p(LP) or p(LP, OS) on risk of local progression after SRS, with death as a competing risk. RESULTS Ninety-two patients and 391 lesions were identified. At the patient level, one-year LP was 0.08 (95%CI, 0.03-0.15), median p(LP,OS) was 0.13 (95%, CI 0.07-0.2), and median p(LP) was 0.29 (95% CI, 0.22-0.38). At the metastasis level, one-year LP was 0.02 (95%CI, 0.01-0.04), median p(LP,OS) was 0.05 (95%, CI 0.02-0.07), and median p(LP) was 0.10 (95% CI, 0.07-0.13). p(LP,OS) was significantly associated with the risk of local progression at the patient level (p=0.048) and metastasis level (p=0.007); however, p(LP) was not (p=0.16 and p=0.28, respectively). CONCLUSION This study suggests simultaneous OS and TCP modeling more accurately predicts LP than TCP modeling alone. Better understanding which patients are at risk of LP after SRS may help personalize treatment to minimize risk without sacrificing efficacy.

Feasibility of Cognitive-Sparing Stereotactic Radiosurgery for Brain Metastases: Initial Report of Phase II COG-SRS Trial

Radiotherapy at high doses leads to white matter (WM) and hippocampal injury which can cause cognitive decline. We designed the first, to our knowledge, evidence-based cognitive sparing brain SRS trial for patients with limited brain metastases. In this report we analyze feasibility of cognitive-sparing SRS, utilizing dose constraints for eloquent WM tracts and bilateral hippocampi. This is a single-institution phase II NCI-funded clinical trial (NCT04343157) of cognitive-sparing brain SRS; eloquent regions of interest (ROI) and associated cognitive domains are outlined in Table 1. Patients underwent high-resolution quantitative diffusion and volumetric MRI at baseline and post-SRS follow-up. Comprehensive neurocognitive assessment was performed at baseline and 3 months post-SRS by a neuropsychologist evaluating different neurocognitive domains (Table 1). Clinical processing/workflow was largely automated with robust, validated segmentation tools of eloquent WM tracts and the hippocampi. Single fraction dose constraints to WM tracts were 12 Gy Dmax and 8.4 Gy to hippocampi with 3 and 5 fraction equivalent doses, based on our prior NTCP studies. Patient accrual, follow up imaging and neurocognitive testing is still active. To date, n = 59 patients and 114 lesions have been treated with cognitive-sparing Linac-based SRS on trial. Median age is 63 years. Lung cancer was the most common primary (35.6%), along with breast cancer (23.7%) and melanoma (15.3%). Patients had 1-4 brain metastases; median prescription dose was 24 Gy/1, 27 Gy/3, or 30 Gy/5 depending on target volume. Most patients were treated < 7 business days from MRI. Cognitive endpoints have been collected on 89.5% of patients. Cognitive sparing constraints were met in 79.3% of plans while maintaining standard clinical SRS plan indices and coverage benchmarks. 38.9% of the plans that failed to meet the Dmax constraint kept D0.03cc under constraints. Plans going over constraints had tumors overlying or within 1 mm of eloquent ROIs. Local control for treated lesions at 6 months was 97.9% and 95.7% at 12 months. Distant intracranial control was 68.1% at 6 and 12 months. Median OS was 18 months. Cognitive-sparing SRS treatment planning was successfully implemented for the majority of treated lesions with excellent local control. Mitigation of damage to eloquent structures has potential to further reduce cognitive decline after SRS. Full neurocognitive outcomes will be reported after accrual and testing are complete.

P11.37.B RADIOSURGERY-ASSOCIATED NEW-ONSET FACIAL SPASM AFTER THE TREATMENT OF VESTIBULAR SCHWANNOMA IS ASSOCIATED WITH INCIDENCE OF RECURRENCE

Abstract BACKGROUND Facial function preservation in the care of vestibular schwannoma (VS) is pre-dominantly measured in motoric function (e.g. House-Brackman (HB)). Facial spasm (FS) has been reported to be a possible side-effect in the radiosurgical treatment of VS. However, the exact incidence of FS is still unclear. MATERIAL AND METHODS This study aims to study the incidence of FS in the treatment of VS. Patient medical records of patients treated by treatment of VS between 2004 and 2020 ere analyzed retrospectively. Patient and tumor characteristics were analyzed (i.e., sex, age, tumor extension and size, intracanalicular extension). RESULTS N=104/1’998 (5%) of all patients treated by SRS presented with new-onset FS postinterventionally. FS was unrelated to tumor size. The incidence of new-onset FS was significantly higher in women (6%) compared to men (4%) (p=0.032). From all patients with FS, N=24/104 (23%) of new onset FS appeared after Re-SRS (second SRS treatment). In primary SRS therapy, facial spasm was associated with a higher recurrence rate of N=20/80 (25%) vs N=252/1"894 (13%) in nonFS patients (p=0.007). N=65/104 (62%) were permanent FS, whereas N=41/104 (39%) recovered spontaneously between 4 and 34 months, postinterventionally. The proportion (76%) of FS patients had tumors with extensive intra-canalicular extension (OHATA A-B) was higher in compared to a nonFS control group (64%) (p=0.015). CONCLUSION FS is a SRS therapy-related side effect with an overall incidence of 5%. Women were more commonly affected by new-onset SRS. Second-line SRS has the highest risk for new-onset FS. FS was associated with a higher incidence of recurrence compared to non-FS VS patients. Patients" consultation should address the relevant side effect.

28 Measurement of Neutron Dose for VMAT and SRS Treatment at Energies Between 6 and 10 MV

28 Measurement of Neutron Dose for VMAT and SRS Treatment at Energies Between 6 and 10 MV

285 Optimizing the Deliverability of Binary Collimation-Based SRS Treatment Technique for Multiple Metastases with Multiple Prescriptions

285 Optimizing the Deliverability of Binary Collimation-Based SRS Treatment Technique for Multiple Metastases with Multiple Prescriptions